Logos Global Management LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001792126
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2026 · 63 positions · Total reported value $1.89B · Top-10 concentration 50.7% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 72.7% · 25 new · 19 cut · 20 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +22.9% · vs SPY +8.1% · Prev Value $1.89B — last quarter positions weighted by this quarter price moves · ranking
In its Q1 2026 13F filing, Logos Global Management LP disclosed 63 equity positions with a combined reported value of $1.89B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 50.7% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2026 were RVMD ($194.50M), ERAS ($180.41M), IDYA ($114.95M). By sector, the heaviest allocations are Health Care 93.6%, Other 6.4%. Versus the prior quarter, allocation shifted toward Health Care (+7.3pp) and away from Other (-7.3pp).
Versus the prior quarter, Logos Global Management LP opened 25 new positions, trimmed 19 and fully exited 20, a turnover rate of 72.7% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q1 2026 were UTHR ($47.44M), MDGL ($44.49M), XENE ($26.17M).
Of the 20 positions fully exited versus the prior quarter, the largest were CDTX ($68.48M), RNAM ($36.06M), JAZZ ($34.00M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2026)
- UTHR UNITED THERAPEUTICS CORP DEL · $47.44M
- MDGL MADRIGAL PHARMACEUTICALS INC · $44.49M
- XENE XENON PHARMACEUTICALS INC · $26.17M
- ALKS ALKERMES PLC · $12.38M
- TENX TENAX THERAPEUTICS INC · $9.99M
- AVBP ARRIVENT BIOPHARMA INC COM · $8.07M
- RLAY RELAY THERAPEUTICS INC COM · $7.46M
- MGTX MEIRAGTX HLDGS PLC COM · $6.06M
Fully Exited (vs previous quarter)
- CDTX CIDARA THERAPEUTICS INC · prev qtr: $68.48M
- RNAM AVIDITY BIOSCIENCES INC · prev qtr: $36.06M
- JAZZ JAZZ PHARMACEUTICALS PLC · prev qtr: $34.00M
- APLS APELLIS PHARMACEUTICALS INC · prev qtr: $25.12M
- QURE UNIQURE NV · prev qtr: $16.15M
- KNSA KINIKSA PHARMACEUTICALS INTL P ORD SHS CL A · prev qtr: $14.44M
- KYMR KYMERA THERAPEUTICS INC · prev qtr: $10.12M
- NRIX NURIX THERAPEUTICS INC · prev qtr: $9.48M
Insider Transactions (Form 4)
Latest Logos Global Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Logos Global Management LP is an SEC-registered 13F filer based in San Francisco, CA, United States. As of Q2 2026 it reported 68 US equity positions with a combined value of $2.32B. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Firm Snapshot
- Headquarters: SAN FRANCISCO, CA, United States
- SEC registration: 801-117248 (status: Approved), registered 2019-08-26
- Regulatory AUM (Form ADV): $2.25B as of 2026-04-22
- Client mix (by RAUM): pension and profit-sharing plans 100%
- Manages 5 private funds, of which 1 hedge funds
Portfolio Structure
- 68 positions · $2.32B reported value (Q2 2026)
- Top 10 holdings = 48.3% of reported value
- Largest position: ERAS (ERASCA INC COM) at 9.6%
- Average position size: $34.16M
Sector Tilt
- Health Care 99.1%
- Financials 0.1%
- (classified holdings cover 99% of value)
Quarterly Activity
- Q2 2026: 25 new, 18 added, 19 reduced, 20 exited
- 6 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
2.00M | $194.50M | 10.30% | Add | |
| 2 |
|
11.15M | $180.41M | 9.56% | Reduce | |
| 3 |
|
3.45M | $114.95M | 6.09% | Add | |
| 4 |
|
285.00K | $91.82M | 4.86% | Reduce | |
| 5 |
|
2.12M | $84.41M | 4.47% | Add | |
| 6 |
|
675.00K | $75.16M | 3.98% | Add | |
| 7 |
|
3.00M | $62.76M | 3.33% | Reduce | |
| 8 |
|
875.00K | $57.67M | 3.06% | Add | |
| 9 |
|
3.21M | $47.84M | 2.53% | Hold | |
| 10 |
|
80.00K | $47.44M | 2.51% | New | |
| 11 |
|
1.50M | $45.23M | 2.40% | Add | |
| 12 |
|
85.00K | $44.49M | 2.36% | New | |
| 13 |
|
450.00K | $39.14M | 2.07% | Add | |
| 14 |
|
575.00K | $38.92M | 2.06% | Add | |
| 15 |
|
1.24M | $36.86M | 1.95% | Add | |
| 16 |
|
200.00K | $36.67M | 1.94% | Hold | |
| 17 |
|
560.00K | $35.81M | 1.90% | Add | |
| 18 |
|
400.00K | $33.57M | 1.78% | Add | |
| 19 |
|
3.85M | $32.61M | 1.73% | Add | |
| 20 |
|
850.00K | $32.55M | 1.73% | Add | |
| 21 |
|
2.40M | $28.63M | 1.52% | Add | |
| 22 |
|
1.50M | $27.96M | 1.48% | Reduce | |
| 23 |
|
1.07M | $26.70M | 1.42% | Reduce | |
| 24 |
|
500.00K | $26.36M | 1.40% | Reduce | |
| 25 |
|
450.00K | $26.17M | 1.39% | New | |
| 26 |
|
1.20M | $25.92M | 1.37% | Add | |
| 27 |
|
1.40M | $25.38M | 1.34% | Add | |
| 28 |
|
500.00K | $24.10M | 1.28% | Reduce | |
| 29 |
|
915.00K | $22.56M | 1.20% | Reduce | |
| 30 |
|
1.95M | $20.75M | 1.10% | Reduce | |
| 31 |
|
500.00K | $19.60M | 1.04% | Add | |
| 32 |
|
3.21M | $19.37M | 1.03% | Reduce | |
| 33 |
|
600.00K | $19.21M | 1.02% | Add | |
| 34 |
|
200.00K | $18.48M | 0.98% | Reduce | |
| 35 |
|
300.00K | $17.43M | 0.92% | Reduce | |
| 36 |
|
750.00K | $16.70M | 0.88% | Reduce | |
| 37 |
|
3.15M | $16.66M | 0.88% | Add | |
| 38 |
|
450.00K | $14.27M | 0.76% | Add | |
| 39 |
|
1.00M | $13.90M | 0.74% | Hold | |
| 40 |
|
750.00K | $13.38M | 0.71% | Add | |
| 41 |
|
350.00K | $12.38M | 0.66% | New | |
| 42 |
|
950.00K | $12.04M | 0.64% | Add | |
| 43 |
|
1.23M | $11.16M | 0.59% | Add | |
| 44 |
|
625.00K | $9.99M | 0.53% | New | |
| 45 |
|
700.00K | $9.73M | 0.52% | Reduce | |
| 46 |
|
482.50K | $8.86M | 0.47% | Reduce | |
| 47 |
|
250.00K | $8.37M | 0.44% | Reduce | |
| 48 |
|
350.00K | $8.07M | 0.43% | New | |
| 49 |
|
750.00K | $7.46M | 0.40% | New | |
| 50 |
|
450.00K | $6.58M | 0.35% | Reduce | |
FAQ
What did Logos Global Management LP buy in 2026-Q1?
In its 2026-Q1 13F filing, Logos Global Management LP reported 63 equity positions worth $1.89B in aggregate; its largest disclosed positions were RVMD ($194.50M), ERAS ($180.41M), IDYA ($114.95M).
How large is Logos Global Management LP's portfolio?
Logos Global Management LP reported $1.89B of long equity holdings across 63 positions as of 2026-Q1. Top-10 holdings account for 50.7% of reported value.
What is Logos Global Management LP's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.